We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.49B
AUM Growth
+$287M
Cap. Flow
+$532M
Cap. Flow %
11.84%
Top 10 Hldgs %
50.53%
Holding
128
New
23
Increased
12
Reduced
25
Closed
8

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$173M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$75.9M
3
NVAX icon
Novavax
NVAX
+$49.8M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$43.3M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.5M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$71.6M
2
VIE
Viela Bio, Inc. Common Stock
VIE
+$51.4M
3
IMVT icon
Immunovant
IMVT
+$32.3M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$30.6M
5
KURA icon
Kura Oncology
KURA
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
76
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8.97M 0.2%
200,000
– –
TNGX icon
77
Tango Therapeutics
TNGX
$4.41B
$8.9M 0.2%
800,000
– –
FDMT icon
78
4D Molecular Therapeutics
FDMT
$562M
$8.68M 0.19%
200,000
– –
QURE icon
79
uniQure
QURE
$3.22B
$8.42M 0.19%
250,000
– –
ARGX icon
80
argenx
ARGX
$54.1B
$8.26M 0.18%
30,000
– –
GOSS icon
81
Gossamer Bio
GOSS
$87M
$7.85M 0.17%
848,382
– –
VRDN icon
82
Viridian Therapeutics
VRDN
$2.67B
$7.67M 0.17%
459,144
+366,018
+393% +$6.85M
MRUS
83
DELISTED
Merus
MRUS
$7.31M 0.16%
350,000
– –
DNTH icon
84
Dianthus Therapeutics
DNTH
$6.09B
$7.1M 0.16%
+37,500
New +$6.31M
AKUS
85
DELISTED
Akouos Inc
AKUS
$6.93M 0.15%
499,989
-1
-0% -$18
GTH
86
DELISTED
Genetron Holdings Limited ADS
GTH
$6.44M 0.14%
100,000
-33,333
-25% -$2.29M
IRON icon
87
Disc Medicine
IRON
$2.97B
$6.44M 0.14%
+15,833
New +$7.06M
CGEM icon
88
Cullinan Oncology
CGEM
$1.14B
$6.25M 0.14%
+150,000
New +$6.09M
QTNT
89
DELISTED
Quotient Limited Ordinary Shares
QTNT
$5.52M 0.12%
37,500
– –
TARA icon
90
Protara Therapeutics
TARA
$232M
$5.51M 0.12%
350,000
– –
IMVT icon
91
Immunovant
IMVT
$8.25B
$5.41M 0.12%
337,048
-1,225,904
-78% -$32.3M
BLSA
92
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.29M 0.12%
500,000
– –
PNT
93
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.25M 0.12%
500,000
– –
SRPT icon
94
Sarepta Therapeutics
SRPT
$1.77B
$5.22M 0.12%
70,000
– –
FVAM
95
DELISTED
5:01 Acquisition Corp
FVAM
$4.99M 0.11%
500,000
– –
VSPRU
96
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
$4.62M 0.1%
400,000
– –
BCEL
97
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.5M 0.1%
293,500
– –
MLTX icon
98
MoonLake Immunotherapeutics
MLTX
$1.55B
$4.39M 0.1%
430,000
– –
REPL icon
99
Replimune Group
REPL
$1.01B
$3.81M 0.09%
125,000
– –
TIL icon
100
Instil Bio
TIL
$50.3M
$3.76M 0.08%
+7,500
New +$3.85M
2 3
4
5 6

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Cormorant Asset Management held 128 positions worth $4.49B, up 6.8% from $4.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Cormorant Asset Management deployed $532M of net new capital in Q1 2021, opening 23 new positions and adding to 12 existing holdings. Its largest new stake was Design Therapeutics: 5,114,850 shares worth $146M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $71.6M trimmed.

  • Cormorant Asset Management's largest Q1 2021 buy was Design Therapeutics: 5,114,850 shares worth $146M.
  • Cormorant Asset Management added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2021, an estimated $42.5M increase.
  • Cormorant Asset Management's biggest Q1 2021 reduction was Beam Therapeutics, cutting an estimated $71.6M.
  • Cormorant Asset Management fully exited Viela Bio, Inc. Common Stock in Q1 2021, selling an estimated $51.4M.
  • Cormorant Asset Management's ten largest holdings make up 51% of its $4.49B portfolio in Q1 2021.
  • Cormorant Asset Management opened 23 new positions and closed 8 in Q1 2021.
  • Cormorant Asset Management's portfolio value rose 6.8% quarter-over-quarter to $4.49B.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.